{"DataElement":{"publicId":"3295822","version":"1","preferredName":"Person Prostate Carcinoma Risk Factor Clinical Trial Eligibility Criteria Type","preferredDefinition":"a subdivision of a particular kind of thing related to anything that increases a person's chance of developing a disease in a person having one of the most common malignant tumors afflicting men as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3295816v1.0:3295817v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3295816","version":"1","preferredName":"Person Prostate Carcinoma Risk Factor Clinical Trial Eligibility Criteria","preferredDefinition":"information related to anything that increases a person's chance of developing a disease in a person having one of the most common malignant tumors afflicting men as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3295814v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3295814","version":"1","preferredName":"Prostate Carcinoma Risk Factor Clinical Trial Eligibility Criteria","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:Anything that increases a person's chance of developing a disease. Some examples of risk factors for cancer include a family history of cancer, use of tobacco products, certain foods, exposure to radiation or cancer-causing agents, and certain genetic alterations.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C4863:C17103:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Risk Factor","conceptCode":"C17103","definition":"Any aspect of an individual's life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-987A-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"ONEDATA","dateModified":"2011-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-988B-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3295817","version":"1","preferredName":"Person Prostate Carcinoma Risk Factor Clinical Trial Eligibility Criteria Type","preferredDefinition":"a subdivision of a particular kind of thing for risk factor of prostate cancer as an eligibility criteria.","longName":"3295817v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"150","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Gleason 7, PSA >= 20-150, any T-stage","valueDescription":"Gleason 7, PSA >= 20-150, any T-stage","ValueMeaning":{"publicId":"3295818","version":"1","preferredName":"Gleason 7, PSA >= 20-150, any T-stage","longName":"3295818","preferredDefinition":"Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a shorter distinct C-terminus. A serine protease in seminal plasma, PSA may function in liquefaction of seminal coagulum by (preferential Tyr-X) cleavage of seminal vesicle protein. Kallikrein proteases have diverse functions. Mounting evidence implicates kallikreins in carcinogenesis; some have potential as cancer biomarkers. The serum level of PSA is useful in diagnosis and monitoring of prostatic carcinoma. (from LocusLink, Swiss-Prot, OMIM, and NCI): A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A number with no fractional part, including the negative and positive numbers as well as zero.::20-150: One, some, every, or all without specification.: One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Greater Than or Equal To","conceptCode":"C61583","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Any","conceptCode":"C81168","definition":"One, some, every, or all without specification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score 7","conceptCode":"C28091","definition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-98B3-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFB3BF6E-98CC-38C1-E040-BB89AD432BD2","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"ONEDATA","dateModified":"2011-10-19","deletedIndicator":"No"},{"value":"Gleason 8, PSA >= 20-150, any T-stage","valueDescription":"Gleason 8, PSA >= 20-150, any T-stage","ValueMeaning":{"publicId":"3295819","version":"1","preferredName":"Gleason 8, PSA >= 20-150, any T-stage","longName":"3295819","preferredDefinition":"Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a shorter distinct C-terminus. A serine protease in seminal plasma, PSA may function in liquefaction of seminal coagulum by (preferential Tyr-X) cleavage of seminal vesicle protein. Kallikrein proteases have diverse functions. Mounting evidence implicates kallikreins in carcinogenesis; some have potential as cancer biomarkers. The serum level of PSA is useful in diagnosis and monitoring of prostatic carcinoma. (from LocusLink, Swiss-Prot, OMIM, and NCI): A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A number with no fractional part, including the negative and positive numbers as well as zero.::20-150: One, some, every, or all without specification.: One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Greater Than or Equal To","conceptCode":"C61583","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Any","conceptCode":"C81168","definition":"One, some, every, or all without specification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score 8","conceptCode":"C28092","definition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-98D6-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFB3BF6E-98EF-38C1-E040-BB89AD432BD2","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"ONEDATA","dateModified":"2011-10-19","deletedIndicator":"No"},{"value":"Gleason 8, PSA < 20, and >= T2","valueDescription":"Gleason 8, PSA < 20, and >= T2","ValueMeaning":{"publicId":"3295820","version":"1","preferredName":"Gleason 8, PSA < 20, and >= T2","longName":"3295820","preferredDefinition":"Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a shorter distinct C-terminus. A serine protease in seminal plasma, PSA may function in liquefaction of seminal coagulum by (preferential Tyr-X) cleavage of seminal vesicle protein. Kallikrein proteases have diverse functions. Mounting evidence implicates kallikreins in carcinogenesis; some have potential as cancer biomarkers. The serum level of PSA is useful in diagnosis and monitoring of prostatic carcinoma. (from LocusLink, Swiss-Prot, OMIM, and NCI): A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::20: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score 8","conceptCode":"C28092","definition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-98F9-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFB3BF6E-9912-38C1-E040-BB89AD432BD2","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"ONEDATA","dateModified":"2011-10-19","deletedIndicator":"No"},{"value":"Gleason >=9, PSA <= 150, any T-stage","valueDescription":"Gleason >=9, PSA <= 150, any T-stage","ValueMeaning":{"publicId":"3392041","version":"1","preferredName":"Gleason >=9, PSA <= 150, any T-stage","longName":"3392041","preferredDefinition":"Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a shorter distinct C-terminus. A serine protease in seminal plasma, PSA may function in liquefaction of seminal coagulum by (preferential Tyr-X) cleavage of seminal vesicle protein. Kallikrein proteases have diverse functions. Mounting evidence implicates kallikreins in carcinogenesis; some have potential as cancer biomarkers. The serum level of PSA is useful in diagnosis and monitoring of prostatic carcinoma. (from LocusLink, Swiss-Prot, OMIM, and NCI): A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.: A number with no fractional part, including the negative and positive numbers as well as zero.::150: One, some, every, or all without specification.: One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Less Than or Equal To","conceptCode":"C61586","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Any","conceptCode":"C81168","definition":"One, some, every, or all without specification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score 10","conceptCode":"C28094","definition":"A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA0D2B67-60F1-6203-E040-BB89AD4344A5","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA0D2B67-610A-6203-E040-BB89AD4344A5","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-28","modifiedBy":"ONEDATA","dateModified":"2012-02-28","deletedIndicator":"No"},{"value":"Gleason score 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml","valueDescription":"Gleason Score 7 Gleason Score 8 Gleason Score 9 Gleason Score 10 T1c Stage Finding T2a Stage Finding T2b Stage Finding Palpation PSA Less Than Fifty Nanogram Per Milliliter","ValueMeaning":{"publicId":"3783624","version":"1","preferredName":"Gleason Score 7 Gleason Score 8 Gleason Score 9 Gleason Score 10 T1c Stage Finding T2a Stage Finding T2b Stage Finding Palpation PSA Less Than Fifty Nanogram Per Milliliter","longName":"3783624","preferredDefinition":"No Value Exists: No Value Exists: No Value Exists: No Value Exists: A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.: A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.: A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and  is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.:","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 7","conceptCode":"C28091","definition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"12"},{"longName":"Gleason Score 8","conceptCode":"C28092","definition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"Gleason Score 9","conceptCode":"C28093","definition":"A Gleason score that indicates a high-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Gleason Score 10","conceptCode":"C28094","definition":"A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"T1c TNM Finding","conceptCode":"C48723","definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"T2a TNM Finding","conceptCode":"C48725","definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"T2b TNM Finding","conceptCode":"C48726","definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Palpation","conceptCode":"C16950","definition":"A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient's body to examine the size, consistency, texture, location and tenderness of an organ or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fifty","conceptCode":"C105785","definition":"A natural number greater than forty-nine and less than fifty-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nanogram","conceptCode":"C48516","definition":"The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Per Milliliter","conceptCode":"C103452","definition":"A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DEF95B41-B8FD-E633-E040-BB89AD430D85","latestVersionIndicator":"Yes","beginDate":"2013-06-12","endDate":null,"createdBy":"PATELV","dateCreated":"2013-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DEF95B41-B916-E633-E040-BB89AD430D85","beginDate":"2013-06-12","endDate":null,"createdBy":"PATELV","dateCreated":"2013-06-12","modifiedBy":"ONEDATA","dateModified":"2013-06-12","deletedIndicator":"No"},{"value":"Gleason Score 6 + T1c-T2b (palpation) + PSA > 20 ng/ml","valueDescription":"Gleason Score 6  And T1c - T2b Stage (Palpation) And PSA > 20 ng/mL","ValueMeaning":{"publicId":"3791533","version":"1","preferredName":"Gleason Score 6  And T1c - T2b Stage (Palpation) And PSA > 20 ng/mL","longName":"3791533","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.: Used as a function word to indicate direction, purpose, or movement.: A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and  is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.: Examination by pressing on the surface of the body to feel the organs or tissues underneath.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a sh","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"T1c TNM Finding","conceptCode":"C48723","definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"T2b TNM Finding","conceptCode":"C48726","definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Palpation","conceptCode":"C16950","definition":"A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient's body to examine the size, consistency, texture, location and tenderness of an organ or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Microgram per Liter","conceptCode":"C67306","definition":"A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFAB0E5E-05AE-B007-E040-BB89AD43433F","latestVersionIndicator":"Yes","beginDate":"2013-06-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFAB0E5E-05C7-B007-E040-BB89AD43433F","beginDate":"2013-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-21","modifiedBy":"ONEDATA","dateModified":"2013-06-21","deletedIndicator":"No"},{"value":"Gleason Score 6 + T2c-T4 (palpation) or > 50% (positive) biopsies + PSA < 50 ng/ml","valueDescription":"Gleason Score 6 And T2c - T4 Stage Finding (Palpation) Or > 50% Positive Biopsy And PSA < 50 ng/mL","ValueMeaning":{"publicId":"3787754","version":"1","preferredName":"Gleason Score 6 And T2c - T4 Stage Finding (Palpation) Or > 50% Positive Biopsy And PSA < 50 ng/mL","longName":"3787754","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::6: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.: Used as a function word to indicate direction, purpose, or movement.: A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.\r\n: Examination by pressing on the surface of the body to feel the organs or tissues underneath.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::6: A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).: An observation confirming something, such as the presence of a disease, condition, or microorganism.: Removal and pathol","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"17"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"16"},{"longName":"T2c TNM Finding","conceptCode":"C48727","definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"15"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"14"},{"longName":"T4 TNM Finding","conceptCode":"C48732","definition":"A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"13"},{"longName":"Palpation","conceptCode":"C16950","definition":"A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient's body to examine the size, consistency, texture, location and tenderness of an organ or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"12"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Percent Unit","conceptCode":"C48570","definition":"A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Biopsy","conceptCode":"C15189","definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Microgram per Liter","conceptCode":"C67306","definition":"A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF6D4793-0B56-DC19-E040-BB89AD43316C","latestVersionIndicator":"Yes","beginDate":"2013-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF6D4793-0B6E-DC19-E040-BB89AD43316C","beginDate":"2013-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-18","modifiedBy":"ONEDATA","dateModified":"2013-06-18","deletedIndicator":"No"},{"value":"Gleason score 6 (3+3) with PSA greater than 10 ng/ml","valueDescription":"Gleason score 6 (3+3) with PSA greater than 10 ng/ml","ValueMeaning":{"publicId":"5837856","version":"1","preferredName":"Gleason score 6 (3+3) with PSA greater than 10 ng/ml","longName":"5837856v1.00","preferredDefinition":"A blood concentration of prostate specific antigen greater than 10 ng/mL._A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PSA Level Greater than Ten","conceptCode":"C137686","definition":"A blood concentration of prostate specific antigen greater than 10 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gleason Score 6","conceptCode":"C28090","definition":"A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"505FA228-9537-44A0-E053-F662850A0C17","latestVersionIndicator":"Yes","beginDate":"2017-05-25","endDate":null,"createdBy":"PATELV","dateCreated":"2017-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505FA228-9550-44A0-E053-F662850A0C17","beginDate":"2017-05-25","endDate":null,"createdBy":"PATELV","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Gleason score 7 (3+4) with PSA less than 10 ng/ml","valueDescription":"Gleason Score 7 Three Four With Prostate-Specific Antigen Less Than Ten Nanogram Per Milliliter","ValueMeaning":{"publicId":"5837857","version":"1","preferredName":"Gleason Score 7 Three Four With Prostate-Specific Antigen Less Than Ten Nanogram Per Milliliter","longName":"5837857","preferredDefinition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: Used to indicate the presence of something or someone.: Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.: A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 7","conceptCode":"C28091","definition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Three","conceptCode":"C66834","definition":"A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Four","conceptCode":"C66835","definition":"A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Prostate-Specific Antigen","conceptCode":"C17525","definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Ten","conceptCode":"C69122","definition":"A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nanogram","conceptCode":"C48516","definition":"The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Per Milliliter","conceptCode":"C103452","definition":"A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"505FA228-9564-44A0-E053-F662850A0C17","latestVersionIndicator":"Yes","beginDate":"2017-05-25","endDate":null,"createdBy":"PATELV","dateCreated":"2017-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505FA228-957D-44A0-E053-F662850A0C17","beginDate":"2017-05-25","endDate":null,"createdBy":"PATELV","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Gleason score 7 (3+4) with PSA greater than or equal to 10 ng/ml","valueDescription":"Per Microliter","ValueMeaning":{"publicId":"2718635","version":"1","preferredName":"Per Microliter","longName":"2718635","preferredDefinition":"A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Per Microliter","conceptCode":"C67254","definition":"A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42E8BE52-736E-6F5A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505FA228-9591-44A0-E053-F662850A0C17","beginDate":"2017-05-25","endDate":null,"createdBy":"PATELV","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-989D-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":"2023.9.22 Added PV concepts for PV Gleason score 6 (3+3) with PSA greater than 10 ng/ml. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171065","version":"1","longName":"RTOG-0924","context":"NRG"}]}],"AlternateNames":[{"name":"3295816v1.0:3295817v1.0","type":"USED_BY","context":"NRG"},{"name":"PROS_CARC_RISK_FACTOR_EC_TYP","type":"Context Short Name","context":"NRG"}],"ReferenceDocuments":[{"name":"Risk group","type":"Preferred Question Text","description":"Risk group","url":null,"context":"CTEP"},{"name":"NRG_CRF_TEXT1","type":"Alternate Question Text","description":"Stratification Group","url":null,"context":"NRG"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB3BF6E-993F-38C1-E040-BB89AD432BD2","latestVersionIndicator":"Yes","beginDate":"2011-10-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-19","modifiedBy":"KRYSTKIA","dateModified":"2017-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}